Table 3. Results of the base-case analysis.
| Treatment | Total cost $ | LYs | ICER $/LY* | QALYs | ICER $/QALY† | |
|---|---|---|---|---|---|---|
| Overall patients | ||||||
| Bevacizumab | 328,717 | 3.317 | NA | 2.526 | NA | |
| Olaparib plus bevacizumab | 447,049 | 3.633 | 374,758 | 2.769 | 487,428 | |
| Patients with BRCA mutations | ||||||
| Bevacizumab | 436,564 | 4.367 | NA | 3.322 | NA | |
| Olaparib plus bevacizumab | 713,630 | 5.812 | 191,649 | 4.433 | 249,579 | |
| Patients with HRD | ||||||
| Bevacizumab | 379,412 | 3.767 | NA | 2.869 | NA | |
| Olaparib plus bevacizumab | 633,406 | 5.045 | 198,739 | 3.850 | 258,859 | |
| Patients with HRD without BRCA mutations | ||||||
| Bevacizumab | 329,147 | 3.265 | NA | 2.486 | NA | |
| Olaparib plus bevacizumab | 502,979 | 4.107 | 206,640 | 3.129 | 270,736 | |
BRCA, breast cancer susceptibility genes; HRD, homologous recombination deficiency; ICER, incremental cost-effectiveness ratio; LY, life-year; NA, not applicable; QALY, quality-adjusted life-year.
*Compared to olaparib plus bevacizumab ($/LY).
†Compared to olaparib plus bevacizumab ($/QALY).